Medical Oncology and Haematology, Cantonal Hospital of Graubuenden, Loestrasse 170, Chur, Switezrland.
Swiss Med Wkly. 2012 Jan 30;142:w13511. doi: 10.4414/smw.2012.13511. eCollection 2012.
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), are currently the treatment backbone. Despite remarkable progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subsets of patients, including the elderly and very elderly and those with highly aggressive disease. This review outlines some of the current treatment strategies for DLBCL and discusses the main issues that affect clinical practice.
弥漫性大 B 细胞淋巴瘤（DLBCL）是西方世界最常见的恶性淋巴瘤类型。它具有侵袭性的自然病史，如果未经治疗，中位生存期不到一年。免疫化学治疗方案，包括抗 CD20 抗体利妥昔单抗，通常与环磷酰胺、多柔比星、长春新碱和泼尼松（CHOP）联合使用，是目前的治疗基础。尽管在提高患者生存率方面取得了显著进展，但对于某些亚组患者，包括老年人和非常老年人以及患有高度侵袭性疾病的患者，临床结局仍不理想。本文综述了 DLBCL 的一些当前治疗策略，并讨论了影响临床实践的主要问题。
